PulmValve Endobronchial Valve Clinical Data: A First-in-Human Case Series

A first-in-human case series describes the technical feasibility and early clinical outcomes of the novel PulmValve endobronchial device for severe heterogeneous emphysema. The data, published by figshare admin karger in 2026, includes results from six male patients, tracking pulmonary function, exercise capacity, and adverse events over a 6-month follow-up period.

Use Cases

• Assessing technical feasibility of a novel endobronchial valve based on procedural success rates described.
• Analyzing early safety signals based on the reported serious adverse events.
• Evaluating short-term clinical efficacy based on changes in FEV1, RV, 6MWT, and SGRQ scores.
• Designing larger controlled studies based on the descriptive clinical signals generated.

Strengths

• Provides detailed quantitative clinical outcomes for six patients, including FEV1, RV, 6MWT, and SGRQ scores.
• Includes a 6-month follow-up period, allowing for observation of variable pulmonary function changes.
• Explicitly reports four serious adverse events with adjudication details.

Limitations

• Dataset scale is very limited with only six patients, as indicated by the case series description.
• Column-level documentation is absent; field semantics must be inferred from the PDF/DOC report.
• Row count is unknown, which may limit suitability assessment for statistical analysis.

Provenance

Source

figshare admin karger

Collection Method

Clinical case series data collection from a first-in-human exploratory study.

Freshness

Last updated 2026-06-04 05:55:17; freshness should be verified.